Cargando…
Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progre...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/ https://www.ncbi.nlm.nih.gov/pubmed/36531025 http://dx.doi.org/10.3389/fonc.2022.978005 |
_version_ | 1784849832264859648 |
---|---|
author | Li, Qizheng Zhang, Xia Fan, Buqun Yang, Yudie Cui, Xiaonan Zhang, Jie Jiang, Kaiteng Zhang, Chunxia Zhang, Bin |
author_facet | Li, Qizheng Zhang, Xia Fan, Buqun Yang, Yudie Cui, Xiaonan Zhang, Jie Jiang, Kaiteng Zhang, Chunxia Zhang, Bin |
author_sort | Li, Qizheng |
collection | PubMed |
description | Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progress of second-line treatment. After the failure of second-line chemotherapy, treatment compliance and the physical tolerance of patients both decrease. Therefore, choosing an appropriate third-line treatment regimen is key to prolonging survival and improving quality of life. As a novel cytotoxic antitumor drug, trifluridine/tipiracil (TAS-102) is composed of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD can directly bind to the DNA of cancer cells to cause DNA dysfunction, thereby exerting antitumor effects. TPI can inhibit the degradation of FTD, thereby increasing its cytotoxicity. The few side effects of TAS-102 has become an important reason why clinicians present it as a treatment option to the patient for consideration, clinical trial data for progression free survival are lacking. The exploration of third-line treatment regimens with drug combinations has attracted much attention. This article reports a case of metastatic colon cancer (RAS/BRAF wild type, pMMR/Non-MSI-H), after failure of first-line and second-line therapies, the patient was eventually treated with anlotinib combined with TAS-102 as the third-line treatment. The treatment has shown good efficacy, with a long PFS benefit for more than 20 months and mild adverse reactions. This case reports demonstrates that anlotinib combined with TAS-102 is a promising third-line treatment regimen for refractory mCRC, and provides proof-of-concept for the clinical exploration of optimal third-line combination treatment regimens. |
format | Online Article Text |
id | pubmed-9748473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97484732022-12-15 Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report Li, Qizheng Zhang, Xia Fan, Buqun Yang, Yudie Cui, Xiaonan Zhang, Jie Jiang, Kaiteng Zhang, Chunxia Zhang, Bin Front Oncol Oncology Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progress of second-line treatment. After the failure of second-line chemotherapy, treatment compliance and the physical tolerance of patients both decrease. Therefore, choosing an appropriate third-line treatment regimen is key to prolonging survival and improving quality of life. As a novel cytotoxic antitumor drug, trifluridine/tipiracil (TAS-102) is composed of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD can directly bind to the DNA of cancer cells to cause DNA dysfunction, thereby exerting antitumor effects. TPI can inhibit the degradation of FTD, thereby increasing its cytotoxicity. The few side effects of TAS-102 has become an important reason why clinicians present it as a treatment option to the patient for consideration, clinical trial data for progression free survival are lacking. The exploration of third-line treatment regimens with drug combinations has attracted much attention. This article reports a case of metastatic colon cancer (RAS/BRAF wild type, pMMR/Non-MSI-H), after failure of first-line and second-line therapies, the patient was eventually treated with anlotinib combined with TAS-102 as the third-line treatment. The treatment has shown good efficacy, with a long PFS benefit for more than 20 months and mild adverse reactions. This case reports demonstrates that anlotinib combined with TAS-102 is a promising third-line treatment regimen for refractory mCRC, and provides proof-of-concept for the clinical exploration of optimal third-line combination treatment regimens. Frontiers Media S.A. 2022-11-30 /pmc/articles/PMC9748473/ /pubmed/36531025 http://dx.doi.org/10.3389/fonc.2022.978005 Text en Copyright © 2022 Li, Zhang, Fan, Yang, Cui, Zhang, Jiang, Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Qizheng Zhang, Xia Fan, Buqun Yang, Yudie Cui, Xiaonan Zhang, Jie Jiang, Kaiteng Zhang, Chunxia Zhang, Bin Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report |
title | Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report |
title_full | Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report |
title_fullStr | Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report |
title_full_unstemmed | Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report |
title_short | Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report |
title_sort | anlotinib combined with tas-102 as the third-line treatment for a patient with metastatic colon cancer: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/ https://www.ncbi.nlm.nih.gov/pubmed/36531025 http://dx.doi.org/10.3389/fonc.2022.978005 |
work_keys_str_mv | AT liqizheng anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT zhangxia anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT fanbuqun anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT yangyudie anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT cuixiaonan anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT zhangjie anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT jiangkaiteng anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT zhangchunxia anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport AT zhangbin anlotinibcombinedwithtas102asthethirdlinetreatmentforapatientwithmetastaticcoloncanceracasereport |